These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37189604)

  • 21. Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure]): Medium-Term and Primary End Point Results.
    Birks EJ; Drakos SG; Patel SR; Lowes BD; Selzman CH; Starling RC; Trivedi J; Slaughter MS; Alturi P; Goldstein D; Maybaum S; Um JY; Margulies KB; Stehlik J; Cunningham C; Farrar DJ; Rame JE
    Circulation; 2020 Nov; 142(21):2016-2028. PubMed ID: 33100036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The paradox of left ventricular assist device unloading and myocardial recovery in end-stage dilated cardiomyopathy: implications for heart failure in the elderly.
    Butler CR; Jugdutt BI
    Heart Fail Rev; 2012 Sep; 17(4-5):615-33. PubMed ID: 22258830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiac recovery following left ventricular assist device therapy: experience of complete device explantation including ventricular patch plasty.
    Gyoten T; Rojas SV; Fox H; Hata M; Deutsch MA; Schramm R; Gummert JF; Morshuis M
    Eur J Cardiothorac Surg; 2021 Apr; 59(4):855-862. PubMed ID: 33367693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversal mechanisms of left ventricular remodeling: lessons from left ventricular assist device experiments.
    Margulies KB
    J Card Fail; 2002 Dec; 8(6 Suppl):S500-5. PubMed ID: 12555165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and Molecular Comparison of Pediatric and Adult Reverse Remodeling With Ventricular Assist Devices.
    Weia BC; Adachi I; Jacot JG
    Artif Organs; 2015 Aug; 39(8):691-700. PubMed ID: 25865791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protocolized screening effectively identifies myocardial recovery following destination therapy left ventricular assist device implantation.
    Smith NJ; Collar N; Duvvuri P; Miles B; Wu R; Szabo A; Gaglianello N; Joyce LD; Joyce DL
    Artif Organs; 2022 Aug; 46(8):1636-1648. PubMed ID: 35319785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Left ventricular assist device unloading effects on myocardial structure and function: current status of the field and call for action.
    Drakos SG; Kfoury AG; Selzman CH; Verma DR; Nanas JN; Li DY; Stehlik J
    Curr Opin Cardiol; 2011 May; 26(3):245-55. PubMed ID: 21451407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recovery from heart failure with circulatory assist: a working group of the National, Heart, Lung, and Blood Institute.
    Reinlib L; Abraham W;
    J Card Fail; 2003 Dec; 9(6):459-63. PubMed ID: 14966786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteopontin: a potential biomarker for heart failure and reverse remodeling after left ventricular assist device support.
    Schipper ME; Scheenstra MR; van Kuik J; van Wichen DF; van der Weide P; Dullens HF; Lahpor J; de Jonge N; De Weger RA
    J Heart Lung Transplant; 2011 Jul; 30(7):805-10. PubMed ID: 21531579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating and Myocardial Cytokines Predict Cardiac Structural and Functional Improvement in Patients With Heart Failure Undergoing Mechanical Circulatory Support.
    Diakos NA; Taleb I; Kyriakopoulos CP; Shah KS; Javan H; Richins TJ; Yin MY; Yen CG; Dranow E; Bonios MJ; Alharethi R; Koliopoulou AG; Taleb M; Fang JC; Selzman CH; Stellos K; Drakos SG
    J Am Heart Assoc; 2021 Oct; 10(20):e020238. PubMed ID: 34595931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group.
    Maybaum S; Mancini D; Xydas S; Starling RC; Aaronson K; Pagani FD; Miller LW; Margulies K; McRee S; Frazier OH; Torre-Amione G;
    Circulation; 2007 May; 115(19):2497-505. PubMed ID: 17485581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of left ventricular assist device therapy on the cardiac proteome and metabolome composition in ischemic cardiomyopathy.
    Shahinian JH; Rog-Zielinska EA; Schlimpert M; Mayer B; Tholen S; Kammerer B; Biniossek ML; Beyersdorf F; Schilling O; Siepe M
    Artif Organs; 2020 Mar; 44(3):257-267. PubMed ID: 31494943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of cardiac resynchronization therapy in an end-stage heart failure patient with a left ventricular assist device as a bridge to recovery. A case report.
    Muratsu J; Hara M; Mizote I; Asano Y; Sakata Y; Saito S; Matsumiya G; Sawa Y; Komuro I
    Int Heart J; 2011; 52(4):246-7. PubMed ID: 21828953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Left ventricular assist device recovery: does duration of mechanical support matter?
    Pham BN; Chaparro SV
    Heart Fail Rev; 2019 Mar; 24(2):237-244. PubMed ID: 30302658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship of myocardial substrate characteristics as assessed by myocardial perfusion imaging and cardiac reverse remodeling levels after cardiac resynchronization therapy.
    Chiang KF; Cheng CM; Tsai SC; Lin WY; Chang YC; Huang JL; Hung GU; Kao CH; Chen SA; Chou P; Chen J
    Ann Nucl Med; 2016 Aug; 30(7):484-93. PubMed ID: 27221816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myocardial Recovery in Patients Receiving Contemporary Left Ventricular Assist Devices: Results From the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS).
    Topkara VK; Garan AR; Fine B; Godier-Furnémont AF; Breskin A; Cagliostro B; Yuzefpolskaya M; Takeda K; Takayama H; Mancini DM; Naka Y; Colombo PC
    Circ Heart Fail; 2016 Jul; 9(7):. PubMed ID: 27402861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study.
    Gold MR; Thébault C; Linde C; Abraham WT; Gerritse B; Ghio S; St John Sutton M; Daubert JC
    Circulation; 2012 Aug; 126(7):822-9. PubMed ID: 22781424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sarcomeric genes involved in reverse remodeling of the heart during left ventricular assist device support.
    Rodrigue-Way A; Burkhoff D; Geesaman BJ; Golden S; Xu J; Pollman MJ; Donoghue M; Jeyaseelan R; Houser S; Breitbart RE; Marks A; Acton S
    J Heart Lung Transplant; 2005 Jan; 24(1):73-80. PubMed ID: 15653383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular changes occurring during reverse remodelling following left ventricular assist device support.
    Birks EJ; George RS
    J Cardiovasc Transl Res; 2010 Dec; 3(6):635-42. PubMed ID: 20820974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Left ventricular dimensions predict risk of appropriate shocks but not mortality in cardiac resynchronization therapy-defibrillator recipients with left bundle-branch block and non-ischemic cardiomyopathy.
    Adelstein EC; Schwartzman D; Jain S; Bazaz R; Wang NC; Saba S
    Europace; 2017 Oct; 19(10):1689-1694. PubMed ID: 27856539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.